65 results about "Additional Therapy" patented technology

A system and method for providing pulsed electrical stimulation to one or both vagus nerve(s) of a patient to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders. The electrical pulses can be provided either unilaterally or bilaterally (left and right vagus nerves) and can be supra-diaphramatic or be sub-diaphramatic. The system comprising implantable stimulator, lead(s), an external stimulator, and a programmer. The implantable stimulator, comprising a pulse generator module, and a stimulus-receiver module which is used in conjunction with an external stimulator. Control circuitry ensures selective operation of one of the modules of the implanted stimulator, at a time. Further, the external stimulator comprises a telemetry module for remotely activating (or de-activating) programs over the internet, to arrive at the optimal program for each patient. Once the optimal “dose” is titrated using the external stimulator, the implanted pulse generator can then be programmed to similar parameters. The external stimulator in conjunction with the implanted stimulus-receiver can override the implanted pulse generator module, to provide extra dose of therapy, and also to conserve the implanted battery. The external stimulator is networked to other computers. Using the networking, a physician situated remotely can monitor and program the devices, as well as, automatically generate invoicing. In one embodiment, the external stimulator also comprises GPS circuitry for locating patient.

Methods, systems, and apparatus for the treatment of heart failure (both systolic and diastolic), hypertension, and arrhythmia in patients by stimulating one or more nerves, particularly peripheral nerves, using neurostimulation are described. The therapeutic treatment is accomplished by applying electrical signals to at least one or more nerves using cutaneous, subcutaneous, implantable, or catheter-based neurostimulation assemblies, alone or in combination with one or more additional therapy or stimulation devices associated with the patient's heart, and/or with one or more therapeutic drug infusions or therapies, such as immune modulation therapy (IMT).

A system and method for an adjustable bio-stream self-selecting system. Through a plethora of inputs, the system associates therapeutic recipes and associated biomarker in a personalized approach to recommending an individual to a specific therapeutic program. Therapeutic programs operate in accordance with personalized inputs suggested by the user and through digital markers and biomarkers, which trigger new recommendations by “knowing” the individual. Each bio-stream contains information utilized within these biomarkers to trigger additional therapy recommendations. Because of the complexity of the plurality of inputs, these biomarkers are managed in a way that enables low latency detections, low bandwidth needs, low processing needs, and less battery needs. The pre-processing of these biomarkers helps additional therapy management and precision medicine across larger global population needs of the system.

The invention provides a system and method for analysis and treatment of a tissue site. The system of the invention includes a probe unit containing one or more tissue sensing and monitoring probes configured to measure one or more parameters indicative of one or more states of the tissue site and one or more tissue treatment probes configured to deliver a treatment to the tissue site. A processor receives signals from the sensing and monitoring probes and determines whether the probe unit is located at the tissue site to be treated. The treatment and monitoring probes are activated in order to monitor the state of the tissue site while the treatment is being delivered to the tissue site. The processor receives signals from the sensing and monitoring probes during delivery of the treatment indicative of the state of the tissue site and determines, as the treatment is being carried out, any one or more of whether the treatment carried out so far is adequate, whether an additional treatment needs to be carried out, and whether the parameters of the treatment or the treatment targets need to be modified.

Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

The method allows pretreatment of an acid gas that can comprise more than 10% H₂S, for example a natural gas or a gas associated with the production of a crude petroleum effluent.

The gas is dehydrated in unit DH, then cooled by heat exchangers E9 to E12 and by expansion carried out through valve V7. Cooling allows part of the H₂S contained in the gas to be condensed. The condensates are separated from the gas in drum B1.

The liquid recovered at the bottom of drum B1 is pumped and injected into well P to be sequestered in an underground reservoir or a geologic structure. The gas discharged at the top of drum B1 is depleted in H₂S. This gas is sent through line 43 to a treating site in order to be subjected to additional treatments prior to being used.

A method, apparatus, and computer program product that provides, among other things, a procedure for the enhanced assessment of attention-related impairments of individuals. Further, the method, apparatus, and computer program product enhances existing assessment instruments by providing a way to reduce diagnostic error through the combining of the results of disparate assessment instruments. Potential users of this product will be any person or organization that diagnoses or treats persons with attentional or cognitive impairments. The method can be used for initial screening and diagnosis of disorders associated with impaired attention, such as ADHD, as well as for treatment and evaluation of the effects of treatments, such as medication or additional therapies.

In embodiments of the invention, there is provided a dialyzer or filter comprising hollow fibers, in which blood flows on the exterior of the hollow fibers, and dialysate or filtrate may flow on the inside. The external surfaces of the hollow fibers may have properties of smoothness and hemocompatibility. The fiber bundle may have appropriate packing fraction and may have wavy fibers. Optimum shear rates and blood velocities are identified. Geometric features of the cartridge, such as pertaining to flow distribution of the blood, may be different for different ends of the cartridge. Air bleed and emboli traps may be provided. Lengthened service life may be achieved by combinations of these features, which may permit additional therapies and applications or better economics.

A method, apparatus, and computer useable medium that provides, among other things, a standardized test protocol for screening and evaluation of attentional impairment using EEG data. Further, the method, apparatus, and computer program product enhances existing psychological, behavioral, and physiological EEG data acquisition systems by introducing a sequential stochastic model procedure, and an intelligent data interpretation component capable of assessing EEG inconsistencies associated attentional impairments. Potential users of this product will be any person or organization that diagnoses or treats persons with attentional or cognitive impairments. The method can be used for initial screening and diagnosis of disorders associated with impaired attention, such as ADHD, as well as for treatment and evaluation of the effects of treatments, such as medication or additional therapies.

The use of BETi as a potential treatment for FSHD is provided. Specifically, the use of BETi, and particularly selective BETi for BRD4, are shown to inhibit DUX4 expression which is expected to result in a decrease in the severity of symptoms of FSHD. Further, the treatments are shown to work when pulsed as opposed to continuous. This allows for a BETi to be supplied to a human in a pulse, and then allows the human to not need any additional treatment for a window at least as long as the one of the treatment pulse.

The invention is an improved rolling ball massager that employs two opposing bearing rings a fixed distance apart to enable free rotation of the housed ball in all directions and under all ordinary massage conditions. A cap over the ball may be adopted to allow the user to apply more pressure on the massager. A handle can be removeably coupled to the cap. The handle may provide a grip and additional therapy value with various features, such as winged tips and arc contours. The handle may be centric or offset on the cap. The massager may have protrusions designed to provide pressure point therapy surfaces. Moreover, the massager may have an intermediate member mating the protrusions, such as a lock-ring assembly, for incorporating the massager as a building block for other devices, such as a foot massage floor stand or a back-scratcher device.

A microneedle insertable in a target cell tissue, including a manipulative end maintained exterior of cell tissue and an insertion end positionable in or adjacent of target cell tissue. A plurality of microtubes are bundled to pass through the needle body and extend to respective distal ends grouped proximally interior of the insertion end. A sensing fiber is extendable from means for sensing for passage through the needle body to a distal end capable of sensing cell tissue parameters. The insertion end and the bundled microtube and sensing fiber distal ends are positionable in or adjacent of cell tissue thereby providing rapid evaluation of cell parameters by optic fiber sensing, fiber sampling of cell parameters, and precise delivery of therapeutic fluids or additional treatment measures. A method is also disclosed of precisely positioning a microneedle having a plurality of microtubes and sensing fibers therein for evaluating and treating cell tissue.

Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y₁₂ inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.

Lyophilizates containing docetaxel and the use thereof in preparing concentrated liquid formulations, and ready to use formulations for injection, as well as such concentrates and ready to use formulations themselves are disclosed in which Tween surfactants are avoided so that hypersensitivity reactions to Tween surfactants can be avoided and docetaxel can be administered at higher doses and/or for longer periods of time and/or for additional treatment cycles.

Embodiments of the present invention include methods for the treatment, prevention, or amelioration of vascular disease in diabetic patients. The methods include both implantation of a stent including a first drug. Some embodiments include additional therapy, such as the co-administration of another drug. Some embodiments involve different stent selection for a diabetic patient compared to a non-diabetic patient.

The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a copper (Cu)-based nanoparticle and a method for making the same. The Cu-based nanoparticles can further be incorporated with additional therapeutic or diagnostic compounds and used for the diagnosis and treatment of tumors.

Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, KBU2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.).